Arch Venture Partners
Biotech Investor · 11 portfolio companies
Portfolio
11
Combined Value
$16.1B
Focus Areas
36
Top Stage
Phase 2
Investment Focus
Portfolio Companies
| Company | Valuation |
|---|---|
| Scholar Rock Holding | $5.1B |
| Tango Therapeutics | $2.8B |
| Beam Therapeutics | $2.5B |
| Maze Therapeutics | $2.3B |
| Rapport Therapeutics | $1.3B |
| MapLight Therapeutics | $796.8M |
| Prime Medicine | $635.5M |
| Neumora Therapeutics | $426.5M |
| Quanterix | $200.9M |
| Unity Biotechnology | $3.4M |
| Altos Labs | — |